Abstract: A method of selecting a ruminating animal having a desirable, hereditable trait is disclosed. The method comprises analyzing in the microbiome of the animal for an amount of a hereditable microorganism which is associated with the hereditable trait, wherein the amount of the hereditable microorganism is indicative as to whether the animal has a desirable hereditable trait.
Type:
Application
Filed:
August 6, 2018
Publication date:
August 6, 2020
Applicants:
The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization, The National Institute for Biotechnology in the Negev Ltd.
Abstract: Described herein are isolated regulatory peptides of protein kinase C, chimeric peptides thereof, and their variants. Use of the described peptides, in compositions and methods for treatment of cellular proliferation pathologies is also described.
Type:
Application
Filed:
February 19, 2018
Publication date:
July 23, 2020
Applicants:
THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD., B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD.
Inventors:
Etta Livneh, Sigal Frost, Esti Yeger-Lotem, Ilan Smoly, Assaf Ben Ari
Abstract: Provided herein piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction. Also provided methods of treatment of diseases associated with said processes, e.g. Alzheimer's disease.
Type:
Grant
Filed:
September 13, 2016
Date of Patent:
December 17, 2019
Assignee:
THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD.
Inventors:
Varda Shoshan-Barmatz, Arie Lev Gruzman
Abstract: The present invention relates to use of small organic compounds interacting with the Voltage-Dependent Anion Channel (VDAC) for the treatment of diseases associated with central nervous system (CNS) disorders, including psychotic disorders, mood disorders, neurodegenerative diseases. In particular the present invention relates to the use of substituted piperazine- and piperidine-derivatives and pharmaceutical compositions comprising same for the treatment of psychotic disorders including schizophrenia, mood disorders, and neurodegenerative diseases.
Type:
Grant
Filed:
September 11, 2017
Date of Patent:
October 8, 2019
Assignee:
The National Institute for Biotechnology in the Negev Ltd.
Inventors:
Varda Shoshan-Barmatz, Arie Lev Gruzman
Abstract: The present invention relates to peptides comprising analogues of VDAC1-derived peptides having improved pharmacokinetic characteristics compared to the native parent peptides, which are effective in impairing cell energy production, in inducing apoptosis and cell death, particularly of cancerous cells, in eliminating cancer stem cells and in reducing symptoms associated with fat accumulation in liver cells particularly with nonalcoholic fatty liver disease (NAFLD) and symptoms associated thereto.
Type:
Grant
Filed:
January 11, 2018
Date of Patent:
August 20, 2019
Assignees:
B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY, THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD.
Abstract: Provided are RNA inhibitory molecules, particularly siRNA molecules silencing the expression of Voltage-Dependent Ion Chanel-1 (VDAC1) for the induction of cancer stem cell differentiation and reduction of TAMs abundance and tumor angiogenesis, thereby preventing tumor invention and recurrence.
Type:
Application
Filed:
November 10, 2016
Publication date:
November 15, 2018
Applicants:
B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY, THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD.
Abstract: A protein comprising an amino acid sequence having at least 97% homology to SEQ ID NO: 1. The amino acid sequence comprises valine at position 60, glycine at position 123 and lysine at position 109 and the protein binds hIL17A.
Type:
Grant
Filed:
July 8, 2016
Date of Patent:
December 26, 2017
Assignee:
THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV, LTD.
Abstract: The present invention relates to short peptides based on the amino acids sequence of the N-terminal domain of the human mitochondrial protein voltage-dependent anion channel 1 (VDAC) and to peptide conjugates having a cell permeability enhancing moiety. The peptides, peptide conjugates and pharmaceutical compositions containing them are useful for treating diseases characterized by cell hyperproliferation or resistance to cell death and in particular, cancer.
Type:
Grant
Filed:
July 24, 2014
Date of Patent:
September 12, 2017
Assignees:
B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University, The National Institute for Biotechnology in the Negev Ltd.
Abstract: Provided are engineered soluble hIL-17RA receptors with high affinity to hIL-17 that inhibit downstream IL17A induced signaling events in cells. Also provided are methods of inhibiting hIL-17A induced secretion of CXCL1 and/or IL-6 in cells, as well as methods of treating inflammation and/or inflammatory disorders in a subject.
Type:
Grant
Filed:
July 18, 2012
Date of Patent:
August 16, 2016
Assignee:
The National Institute for Biotechnology in the Negev, Ltd
Abstract: The present invention relates to a reaction plate holding device and system associated therewith for controlling the environment surrounding a reaction plate, and in particular, to a bench-top reaction plate holder providing a controllable environment that fully surrounds a reaction plate.
Type:
Grant
Filed:
March 23, 2012
Date of Patent:
October 28, 2014
Assignee:
The National Institute for Biotechnology in the Negev Ltd.
Abstract: Methods and kits for the detection of cancer and for pre-cancer screening based on the expression of genes associated with altered metabolism and apoptosis in cancerous cells, particularly the expression of a mitochondrial antiviral-signaling (MAVS) or a voltage-dependent anion channel 1 (VDAC1) protein or mRNA in combination with additional genes associated with cell metabolism and/or apoptosis.
Type:
Application
Filed:
March 7, 2014
Publication date:
July 3, 2014
Applicants:
THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD., BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY
Abstract: The present invention provides a photoreactive reagent that binds specifically to Ca2+-binding proteins, links to them covalently after photo-activation, and labels them. The novel reagent enables the characterization, purification, inhibition and screening of Ca2+-binding proteins, as well as the preparation of a new affinity chromatography matrix and a new protein biosensor. The invention also relates to the use of the reagent in inhibiting apoptosis and necrosis and in diagnosing a disorder associated with a defect in the function of a Ca2+-binding protein, and in the preparation of a medicament for treating such disorders.
Type:
Grant
Filed:
February 17, 2005
Date of Patent:
October 11, 2011
Assignee:
The National Institute for Biotechnology in the Negev Ltd.
Inventors:
Varda Shoshan-Bar-Matz, Adrian Israelson